Trial Profile
A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Anacetrapib (Primary)
- Indications Atherosclerosis; Coronary disorders; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa
- Focus Pharmacokinetics
- Sponsors Merck & Co; Merck Sharp & Dohme
- 12 May 2014 New trial record
- 01 May 2014 Results published in the Journal of Clinical Pharmacology.